Press Releases

- Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration

Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020

ASCEND results expected to support STS101 NDA filing in Q4 2021

Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)

More than 1,140 patients randomized and topline results expected in second half 2020

Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations

STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020

On track to announce topline data in second half of 2020 from Phase 3 EMERGE™ efficacy trial evaluating STS101 for the acute treatment of migraine

Completed upsized initial public offering of $90.8 million in gross proceeds

-- Favorable Pharmacokinetic, Safety, and Tolerability Results Support Advancing STS101 into Pivotal Phase 3 Efficacy Trial

-- Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development --

Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019